TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35182418

Group type: EXPERIMENTAL
Intervention: MIB-626 1000 mg once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MIB-626 1000 mg twice daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MIB-626 (both dosages)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 32816504

Group type: EXPERIMENTAL
Intervention: T-SIB (Treatment for Self-Injurious Behaviors)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 33
Study: 36098938

Group type: EXPERIMENTAL
Intervention: TEAS combined with TAPB (group NTG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: TAPB (group NG)
Number of subjects: 90
Study: 33232752

Group type: EXPERIMENTAL
Intervention: Mean arterial oxygen tension (PaO2) between 100 and 180 mmHg
Number of subjects: 491

Group type: COMPARATOR
Intervention: Mean arterial oxygen tension (PaO2) <100 mmHg
Number of subjects: 491

Group type: COMPARATOR
Intervention: Mean arterial oxygen tension (PaO2) >180 mmHg
Number of subjects: 491
Study: 35679043

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation treatment (up to 11 counseling sessions with free medications)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (up to 4 counseling sessions with medication advice)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (referral to the state quitline)
Number of subjects: 0
Study: 33582566

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Time since diagnosis
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Lifestyle factors
Number of subjects: 417
Study: 36383611

Group type: EXPERIMENTAL
Intervention: Colchicine (1.2 mg on day 1 followed by 0.6 mg daily for 13 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 300
Study: 35607981

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) exercise intervention for 6 months
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Low-to-Moderate Intensity (LMI) exercise intervention for 6 months
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Exercise intervention (HI and LMI combined)
Number of subjects: 619

Group type: COMPARATOR
Intervention: High-Intensity (HI) exercise
Number of subjects: 619

Group type: COMPARATOR
Intervention: Low-to-Moderate Intensity (LMI) exercise
Number of subjects: 619

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 619
Study: 33930620

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) education program, 5 home visits over 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) education program
Number of subjects: 60
Study: 32347805

Group type: COMPARATOR
Intervention: Key-in‐based aid (KBA)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Photo‐based aid (PBA)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Gesture‐based aid (GBA)
Number of subjects: 124
Study: 35179802

Group type: EXPERIMENTAL
Intervention: 12 weeks of intermittent fasting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 32249621

Group type: EXPERIMENTAL
Intervention: Kd70 QW (carfilzomib 70 mg/m2 once-weekly plus dexamethasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kd27 BIW (carfilzomib 27 mg/m2 twice-weekly plus dexamethasone)
Number of subjects: 0
Study: 35093547

Group type: EXPERIMENTAL
Intervention: No hip precautions (NP)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Hip precautions (HP)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Both groups (NP and HP)
Number of subjects: 346
Study: 34772395

Group type: EXPERIMENTAL
Intervention: Surgeon-tailored polyethylene mesh
Number of subjects: 27

Group type: COMPARATOR
Intervention: Traditional TOT mesh
Number of subjects: 27
Study: 35429893

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs)
Number of subjects: 9239

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 9239

Group type: EXPERIMENTAL
Intervention: Potentially eligible patients
Number of subjects: 9239

Group type: COMPARATOR
Intervention: Various RCTs
Number of subjects: 9239
Study: 32748229

Group type: EXPERIMENTAL
Intervention: Radiographic classification system for adult idiopathic scoliosis
Number of subjects: 30
Study: 34408026

Group type: EXPERIMENTAL
Intervention: Focus group discussions led by trained facilitators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 0
Study: 32597737

Group type: EXPERIMENTAL
Intervention: Integrative Cognitive Affective Therapy (ICAT-BED)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy Guided Self-Help (CBTgsh)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Both ICAT-BED and CBTgsh
Number of subjects: 78
Study: 34288280

Group type: EXPERIMENTAL
Intervention: ABCT + treatment as usual (TAU)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) + TAU
Number of subjects: 90

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 90
Study: 32521022

Group type: EXPERIMENTAL
Intervention: Topography-guided customized ablation treatment (TCAT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Wavefront-optimized (WFO) photorefractive keratectomy (PRK)
Number of subjects: 23
Study: 32143657

Group type: EXPERIMENTAL
Intervention: SAIA-HTN intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control facilities
Number of subjects: 16
Study: 33962825

Group type: EXPERIMENTAL
Intervention: Higher cancer anxiety, being male, recent screening, family history of breast/prostate cancer, independence in activities of daily living
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Commonly reported reasons for intending to continue screening
Number of subjects: 271
Study: 36286097

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 5982

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 5982
Study: 33884415

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10mg b.d. retreatment
Number of subjects: 0
Study: 36241697

Group type: EXPERIMENTAL
Intervention: 6xR-CHOP + 2R in iPET-negative patients with high mean-SUVAI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (R-)CHOP in iPET-positive patients with high mean-SUVAI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy with CHOP (plus rituximab in CD20-positive lymphomas)
Number of subjects: 0
Study: 33157308

Group type: EXPERIMENTAL
Intervention: Sigh breath (35 cmH2O pressure‐controlled breath over 4 s, once per minute)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Volume Controlled Ventilation (VCV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 20
Study: 33314388

Group type: EXPERIMENTAL
Intervention: Fibrosa layer stripping (FLS) technique
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 70
Study: 34499135

Group type: EXPERIMENTAL
Intervention: Telecare case management program (weekly case management from a nurse via telephone and weekly video messages for 3 months)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (monthly social telephone calls)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Telecare case management program
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 32672795

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg every 3 weeks, 10 mg/kg every 2 weeks, or 10 mg/kg every 3 weeks)
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: Pembrolizumab for BRAF WT melanoma (n=1124)
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: Pembrolizumab for BRAF V600E/K-mutant melanoma (n=434)
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: Pembrolizumab for BRAF V600E/K-mutant melanoma with prior BRAFi (n=271)
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: Pembrolizumab for BRAF V600E/K-mutant melanoma without prior BRAFi (n=163)
Number of subjects: 1558
Study: 34473607

Group type: EXPERIMENTAL
Intervention: IIV4
Number of subjects: 1918
Study: 33236461

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 191218

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100)
Number of subjects: 191218

Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 191218
Study: 37080863

Group type: EXPERIMENTAL
Intervention: Evening light exposure and morning light avoidance
Number of subjects: 57

Group type: COMPARATOR
Intervention: Diet modification (control intervention)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 57
Study: 32694032

Group type: EXPERIMENTAL
Intervention: ACB + iPACK block and continuous ACB (CACB)
Number of subjects: 76

Group type: COMPARATOR
Intervention: ACB + PAI and continuous ACB (CACB)
Number of subjects: 76
Study: 33595208

Group type: EXPERIMENTAL
Intervention: letter-to-future condition
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: letter-from-future condition
Number of subjects: 738

Group type: COMPARATOR
Intervention: control condition
Number of subjects: 738
Study: 33045195

Group type: EXPERIMENTAL
Intervention: Leptin treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study: 35653917

Group type: COMPARATOR
Intervention: POL group (produced in-lab with a polished surface)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CAD/CAM group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CAD/CAM Bur group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DBO group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DBXY group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SiC group (#60-grit silicon carbide sandpaper)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: WS group (#60-grit wood sandpaper)
Number of subjects: 15
Study: 33926921

Group type: EXPERIMENTAL
Intervention: GP2017 (Hyrimoz)
Number of subjects: 1318

Group type: COMPARATOR
Intervention: SB5 (Imraldi)
Number of subjects: 1318
Study: 32340375

Group type: EXPERIMENTAL
Intervention: Increased daily water intake (two additional 550 mL bottles of water consumed daily)
Number of subjects: 55
Study: 33471487

Group type: EXPERIMENTAL
Intervention: ACE+TUDCA treatment for 8 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham ACE+TUDCA treatment for 8 weeks
Number of subjects: 63
Study: 34867786

Group type: EXPERIMENTAL
Intervention: Exenatide treatment
Number of subjects: 182

Group type: COMPARATOR
Intervention: Hypocaloric diet plus placebo injections
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Exenatide responder group
Number of subjects: 182
Study: 32100652

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25(OH)D) levels
Number of subjects: 760
Study: 34265218

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation including nutritional supplements (fish oil with vitamin D3 + whey protein with leucine), exercise and relaxation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 34
Study: 32683400

Group type: EXPERIMENTAL
Intervention: Insulin‐dependent Diabetes Mellitus (IDDM)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Positive GAD65 antibodies
Number of subjects: 305
Study: 35739553

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation for Minimizing the Duration of MV (PROMIZING) study algorithm
Number of subjects: 374
Study: 32297918

Group type: EXPERIMENTAL
Intervention: Baseline objective visual impairment (visual acuity worse than 20/40, 20/80, or 20/100)
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Baseline objective visual impairment
Number of subjects: 1061

Group type: COMPARATOR
Intervention: No baseline visual impairment
Number of subjects: 1061
Study: 35688358

Group type: EXPERIMENTAL
Intervention: Pimitespib 160 mg/day
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Pimitespib (cross-over adjusted)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (after cross-over)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Pimitespib
Number of subjects: 86
Study: 34542212

Group type: EXPERIMENTAL
Intervention: Light Curtain
Number of subjects: 9

Group type: COMPARATOR
Intervention: Care-as-usual activities
Number of subjects: 9
Study: 36311293

Group type: EXPERIMENTAL
Intervention: Esketamine combined with ultrasound-guided pectoral nerve block type II (Pecs II block)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sufentanil for anesthesia induction and PCIA
Number of subjects: 136
Study: 34491652

Group type: EXPERIMENTAL
Intervention: Cotton-moxibustion, applied once a day, 3 cones at a time for 3 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Compound flumetasone ointment, applied twice a day for 3 weeks
Number of subjects: 66
Study: 36220355

Group type: EXPERIMENTAL
Intervention: Multi-component EHR-based intervention
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10000
Study: 34389519

Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment (FBT)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: FBT
Number of subjects: 528
Study: 34018445

Group type: EXPERIMENTAL
Intervention: Lidocaine 4% cream
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 44
Study: 32614394

Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) with heavy external loading (90% of one repetition maximum)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Unloaded ballistic training (UBT) without heavy external loading
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST)
Number of subjects: 36
Study: 35329815

Group type: EXPERIMENTAL
Intervention: 50% Nitrous Oxide-Oxygen (50%N2 O‐O2)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Medical Air (Control)
Number of subjects: 88
Study: 32247073

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 149

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 149
Study: 35922271

Group type: EXPERIMENTAL
Intervention: Guided imagery meditation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 68
Study: 35894916

Group type: EXPERIMENTAL
Intervention: Unilateral home-based strength training (3 sets of 12 repetitions of progressively loaded unilateral calf raises, 3 days per week)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Unilateral home-based strength training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study: 33421039

Group type: EXPERIMENTAL
Intervention: Yoga intervention (1.5 hours of integrated yoga practice every other day for 1 month)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (group discussion session twice a week for 1 month)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Between-group comparison of post-intervention scores
Number of subjects: 53
Study: 32410200

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (low‐level laser therapy) including red light (660 nm), infrared light (840 nm), and infrared laser applied on the first postoperative day
Number of subjects: 60
Study: 33890319

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 34674688

Group type: EXPERIMENTAL
Intervention: SMS-text messaging intervention (4 messages per week)
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1186
Study: 35122442

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) using a diode laser, 808 nm, 250 mW; 16.25 J; 32.5 J cm-2
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical anesthetic gel (Benzocaine 20%)
Number of subjects: 30
Study: 33905482

Group type: EXPERIMENTAL
Intervention: Hyperthermia at 44ºC
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (37ºC)
Number of subjects: 53
Study: 35270420

Group type: EXPERIMENTAL
Intervention: Health Information Package Program plus routine care (n = 98)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Routine care only (n = 98)
Number of subjects: 196
Study: 34754346

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% 15 ml plus ketamine 0.5 mg/kg (LK group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Levobupivacaine 0.5% 15 ml plus 5 ml normal saline (L group)
Number of subjects: 50
Study: 33908182

Group type: EXPERIMENTAL
Intervention: Dimethandrolone undecanoate (DMAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 11β-Methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34233331

Group type: EXPERIMENTAL
Intervention: ACCEPT® (Additive anthroposophic integrative medicine Cancer Concept of Early supportive or Palliative lung cancer Treatment) for 3 months with standard oncological care (SOC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting control group receiving standard oncological care (SOC) only for 3 months
Number of subjects: 20
Study: 36331570

Group type: EXPERIMENTAL
Intervention: Accelerated strategy of renal-replacement therapy (RRT) initiation
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Standard strategy of renal-replacement therapy (RRT) initiation
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Patients with CKD
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Patients without CKD
Number of subjects: 1121
Study: 34806624

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided botulinum toxin injection (50 units of botulinum toxin type A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balloon catheter dilatation therapy (five times per week for two weeks)
Number of subjects: 40
Study: 35568336

Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy (LPI) in 1 randomly selected eye
Number of subjects: 889

Group type: COMPARATOR
Intervention: Untreated control eyes
Number of subjects: 889
Study: 32034202

Group type: EXPERIMENTAL
Intervention: Inhaled milrinone (5 mg) by mesh nebulization
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inhaled milrinone (5 mg) by jet nebulization
Number of subjects: 12
Study: 33203426

Group type: EXPERIMENTAL
Intervention: early palliative radiation
Number of subjects: 74

Group type: COMPARATOR
Intervention: standard of care
Number of subjects: 74
Study: 35739713

Group type: EXPERIMENTAL
Intervention: True air purification treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham air purification treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PM2.5 exposure (outdoor, indoor, and time-weighted personal)
Number of subjects: 24
Study: 33493624

Group type: EXPERIMENTAL
Intervention: Neuronavigated iTBS
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-neuronavigated F3 guided iTBS
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 35645072

Group type: EXPERIMENTAL
Intervention: Chemiluminescence with Lugol's iodine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Chemiluminescence with toluidine blue
Number of subjects: 84
Study: 33037810

Group type: EXPERIMENTAL
Intervention: Zinc gluconate 50 mg daily plus conventional hospital management
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional hospital management
Number of subjects: 49
Study: 36251731

Group type: EXPERIMENTAL
Intervention: Progressive training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomly interleaved training
Number of subjects: 0
Study: 32404731

Group type: EXPERIMENTAL
Intervention: Immunotherapy (2011-2013)
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Immunotherapy (2014)
Number of subjects: 1998

Group type: COMPARATOR
Intervention: Control (no immunotherapy)
Number of subjects: 1998
Study: 34131850

Group type: EXPERIMENTAL
Intervention: Therapeutic Riding (THR)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HeartMath (HM)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 35288291

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 36

Group type: COMPARATOR
Intervention: Localized DVT (Control)
Number of subjects: 36
Study: 32429720

Group type: EXPERIMENTAL
Intervention: Postoperative inosine pranobex immunotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: No postoperative immunotherapy
Number of subjects: 32
Study: 36207508

Group type: EXPERIMENTAL
Intervention: Simultaneous initiation of lixisenatide and basal insulin (BI)
Number of subjects: 2679

Group type: COMPARATOR
Intervention: Sequential initiation of lixisenatide and basal insulin (BI)
Number of subjects: 2679
Study: 33744902

Group type: EXPERIMENTAL
Intervention: Modified triangular prismatic double-J (DJ) stent
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard DJ stent
Number of subjects: 152
Study: 32325856

Group type: EXPERIMENTAL
Intervention: Yeast beta-glucan (YBG) 250 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Maltodextrin placebo (PLA)
Number of subjects: 31
Study: 36126213

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid filler Restylane Defyne
Number of subjects: 140

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 140
Study: 32862111

Group type: EXPERIMENTAL
Intervention: IFN β‐1b (250 mcg subcutaneously every other day for two consecutive weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IFN β‐1b
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (national protocol medications: lopinavir/ritonavir or atazanavir/ritonavir plus hydroxychloroquine for 7–10 days)
Number of subjects: 80
Study: 33541794

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hib-HepB
Number of subjects: 5200

Group type: COMPARATOR
Intervention: Control vaccines
Number of subjects: 5200
Study: 35123553

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel (PTX) with S-1
Number of subjects: 180

Group type: COMPARATOR
Intervention: Gemcitabine plus nab-paclitaxel (GnP)
Number of subjects: 180